• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine.

作者信息

Breccia M, Piciocchi A, Messina M, Soddu S, De Stefano V, Bellini M, Iurlo A, Martino B, Siragusa S, Albano F, Mora B, Fazi P, Vignetti M, Guglielmelli P, Palandri F

机构信息

Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.

GIMEMA Foundation, Franco Mandelli Onlus, Rome, Italy.

出版信息

Leukemia. 2022 Oct;36(10):2548-2550. doi: 10.1038/s41375-022-01675-1. Epub 2022 Aug 13.

DOI:10.1038/s41375-022-01675-1
PMID:35963940
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9375079/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/888f/9375079/506dae76229e/41375_2022_1675_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/888f/9375079/506dae76229e/41375_2022_1675_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/888f/9375079/506dae76229e/41375_2022_1675_Fig1_HTML.jpg

相似文献

1
Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine.费城的新冠病毒-阴性骨髓增殖性肿瘤：一项关于发病率、临床管理和疫苗的GIMEMA调查
Leukemia. 2022 Oct;36(10):2548-2550. doi: 10.1038/s41375-022-01675-1. Epub 2022 Aug 13.
2
Incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the Côte d'Or area, France, during 1980-99.
J Intern Med. 2005 Jul;258(1):90-1. doi: 10.1111/j.1365-2796.2005.01505.x.
3
How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy-a GIMEMA MPN WP survey.意大利冠状病毒大流行如何影响费城阴性慢性骨髓增殖性肿瘤的临床管理——一项GIMEMA MPN WP调查
Leukemia. 2020 Oct;34(10):2805-2808. doi: 10.1038/s41375-020-0953-3. Epub 2020 Jul 3.
4
Age at diagnosis is an important prognostic factor in Philadelphia-negative Myeloproliferative Neoplasms.
Eur J Haematol. 2019 Aug;103(2):140-141. doi: 10.1111/ejh.13266. Epub 2019 Jun 13.
5
Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients?经典的Ph阴性骨髓增殖性肿瘤的当前反应标准是否能让患者获益？
Leukemia. 2012 May;26(5):1148-9. doi: 10.1038/leu.2011.337. Epub 2011 Nov 22.
6
Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.费城染色体阴性经典骨髓增殖性肿瘤的流行病学。
Hematol Oncol Clin North Am. 2021 Apr;35(2):177-189. doi: 10.1016/j.hoc.2020.11.005. Epub 2021 Jan 4.
7
COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey.费城的COVID-19与阴性骨髓增殖性疾病：一项GIMEMA调查。
Leukemia. 2020 Oct;34(10):2813-2814. doi: 10.1038/s41375-020-01032-0. Epub 2020 Aug 25.
8
Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983-99.1983年至1999年期间瑞典哥德堡市慢性费城染色体阴性（Ph-）骨髓增殖性疾病的发病率趋势。
J Intern Med. 2004 Aug;256(2):161-5. doi: 10.1111/j.1365-2796.2004.01357.x.
9
Prevalence of MPL W515L/K mutations in Taiwanese patients with Philadelphia-negative chronic myeloproliferative neoplasms.台湾地区费城染色体阴性慢性骨髓增殖性肿瘤患者中 MPL W515L/K 突变的流行率。
J Chin Med Assoc. 2010 Oct;73(10):530-2. doi: 10.1016/S1726-4901(10)70115-5.
10
[Summary of recommendations for the diagnosis and therapy of BCR/ABL-negative myeloproliferation of the Czech Working Group for Ph-negative myeloproliferative disease (CZEMP) of the Czech Hematologic Society CLS JEP ].
Vnitr Lek. 2012 Feb;58(2):163-8.

引用本文的文献

1
Timing of BNT162b2 vaccine prior to COVID-19 infection, influence disease severity in patients with hematologic malignancies: Results from a cohort study.BNT162b2 疫苗在 COVID-19 感染前的接种时机对血液系统恶性肿瘤患者疾病严重程度的影响：一项队列研究的结果。
Cancer Med. 2023 Nov;12(21):20503-20510. doi: 10.1002/cam4.6397. Epub 2023 Oct 25.
2
Immune Thrombocytopenia Onset and Relapse During the COVID-19 Pandemic. A Monocenter Study.新冠疫情期间免疫性血小板减少症的发病与复发：一项单中心研究
Mediterr J Hematol Infect Dis. 2023 May 1;15(1):e2023029. doi: 10.4084/MJHID.2023.029. eCollection 2023.
3
SARS-CoV-2 vaccination and thrombotic risk in myeloproliferative neoplasms.
严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）疫苗接种与骨髓增殖性肿瘤的血栓形成风险
Res Pract Thromb Haemost. 2023 Feb;7(2):100122. doi: 10.1016/j.rpth.2023.100122. Epub 2023 Mar 15.
4
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine.芦可替尼治疗骨髓纤维化和真性红细胞增多症后，使用BNT162b2 mRNA新冠疫苗进行标准和加强接种会导致体液免疫反应欠佳。
Front Oncol. 2023 Feb 14;13:1117815. doi: 10.3389/fonc.2023.1117815. eCollection 2023.